National Cancer Institute (nci)

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and nerve sheath tumors. The drug is given through a vein and aims to shrink or control tumors. The study will check safety, find the best dose, and see…

This study tests a drug called M3814 (Peposertib) together with a special type of radiation for people with locally advanced pancreatic cancer. The goal is to find the best dose and see if the combination is safe and works better than radiation alone. About 92 adults who have alr…

This early-phase study tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain aggressive lymphomas. About 25 adults with high-risk features will receive up to 6 cycles of treatment…

This study tests whether giving a lower dose of the cancer drug atezolizumab less often can still control tumors while causing fewer side effects. About 30 adults with advanced cancers like lung, liver, or melanoma will receive the drug, with doses adjusted based on blood levels.…

This study compares two treatments for head and neck cancer that has returned or spread and no longer responds to standard platinum chemotherapy. One group gets the immunotherapy drug pembrolizumab alone; the other gets pembrolizumab plus cetuximab, which targets a protein on can…

This early-phase trial tests a combination of two targeted drugs, abemaciclib and olaparib, in people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goal is to find the safest dose and understand side effects. About 42 participants will b…

This study tests a lab-made protein called CYT107 in 55 adults with HIV-related Kaposi sarcoma who have low T-cell counts. The goal is to see if weekly injections for up to 4 weeks can shrink tumors by boosting the immune system. Participants who improve may receive another round…

This study tests whether two drugs, ZEN-3694 and talazoparib, can shrink tumors in people with advanced solid cancers that have spread or cannot be removed. About 88 adults will take part. The study also looks at how a person's genes might affect whether the treatment works. The …

This study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination can shrink tumors. About 36 adults with advanced or metastatic NUT carcino…

This study tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system better fight prostate cancer. About 65 adults with high- or intermediate-risk prostate cancer that hasn't spread will take part. The goal is t…

This study tests a new way to treat early-stage prostate cancer using MRI-guided ultrasound. The procedure, called TULSA, uses heat from a small device placed in the urethra to destroy cancer areas in the prostate. About 21 adults with localized prostate cancer will take part. Th…

This study is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink rare cancers of the urinary and reproductive systems that have spread to other parts of the body. About 314 adults with these rare tumors will receive the drug combo. The…

This study looks at whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after lung cancer surgery can help people live longer without the cancer coming back. About 1,210 adults with stage II to IIIB non-small cell lung cancer that was removed by surgery w…

This early-phase study tests a combination of two drugs—pomalidomide (a pill) and nivolumab (an IV infusion)—in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors or slow disease. Part…

This study tests whether adding an experimental drug (PDS01ADC) to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread. About 86 men aged 18 and older with either castration-sensitive or castration-resistant disease will participate. The goal is to…

This study tests whether a shorter course of radiation can safely treat glioblastoma that has returned after initial treatment. About 28 adults with recurrent grade 4 brain tumors will receive focused radiation 4 times a week for 1 to 3 weeks. The goal is to find the safest sched…

This study compares starting treatment right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants receive two drugs: venetoclax (which blocks a protein that helps cancer cells …

This phase 3 trial compares two antibody drugs—rituximab (standard) and mosunetuzumab (new)—in 600 people with low-tumor follicular lymphoma, a slow-growing blood cancer. The goal is to see which drug better delays cancer progression. Participants receive either drug intravenousl…

This study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV disease will receive either the combination or osimertin…

This early-phase study tests a combination of six drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide, and polatuzumab) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the cocktail is safe and can shrink …

This study tests a drug called binimetinib for people with hairy cell leukemia that lacks the BRAF gene mutation, making standard treatments ineffective. About 40 adults whose cancer returned or didn't respond to prior therapy will take the pill twice daily. The goal is to see if…

This study is for people with a rare type of sinus cancer called sinonasal squamous cell carcinoma. It compares standard chemotherapy alone to chemotherapy plus the immunotherapy drug cemiplimab, both given before surgery. The goal is to see if adding cemiplimab helps stop the ca…

This study tests a combination of up to four experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in adults with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the immune-boosting cocktail can shrink tum…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with other treatments. The goal is to see if th…

This early-stage study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right d…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a standard chemo-immunotherapy combination can better control metastatic triple-negative breast cancer. About 70 participants will receive either the vaccine plus immunotherapy or immunoth…

This study tests a drug called abemaciclib for people with NF1 who have nerve tumors (atypical neurofibromas) that can't be removed by surgery. The goal is to find a safe dose and see if the drug can shrink or control the tumors. Participants take the drug twice daily for up to 2…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…

This early-phase study tests a personalized treatment for people with certain blood cancers, including acute myeloid leukemia and myelodysplastic syndrome. Researchers take a patient's own immune cells, modify them in the lab to recognize unique markers on their cancer cells, and…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy helps more infants with acute lymphoblastic leukemia (ALL) achieve remission. About 153 infants under 1 year old with newly diagnosed ALL will take part. The goal is to see i…

This study aims to see if adjusting the dose of the cancer drug belinostat based on a person's genes can make treatment safer and more effective for people with high-grade neuroendocrine carcinomas. Participants will receive belinostat along with two other chemotherapy drugs, and…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 170 adults aged 18 to 72 who have already tried at least one other treatment will take part.…

This early-phase study tests whether a customized immune cell therapy (anti-CD22 CAR T cells) is safe for people with hairy cell leukemia (classic or variant) that has returned or not responded to standard treatments. Up to 27 adults will receive the therapy after mild chemothera…

This study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…

This early-phase study tests two drugs together—DS-8201a and olaparib—in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors. About 55 adults with certain solid tumors or…

This study tests whether a combination of two drugs (pembrolizumab and N-803) with or without special immune cells can help shrink head and neck cancers before surgery. About 40 adults with advanced, untreated head and neck cancer will receive the treatment for about 3 weeks befo…

This study tests a drug called selinexor combined with standard radiation for children and young adults with newly diagnosed aggressive brain tumors (DIPG or H3 K27M-mutant high-grade glioma). The goal is to find the safest dose and see if the combination can shrink tumors. About…

This study tests whether taking iberdomide pills after CAR-T therapy can keep multiple myeloma under control longer than just watching and waiting. About 78 people who have already received the CAR-T treatment idecabtagene vicleucel will be randomly assigned to either take iberdo…

This early-stage trial tests whether adding an experimental drug (ZEN003694) to a standard chemotherapy (capecitabine) is safe and tolerable for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 adults whose cancer has worsened after stan…

This early-stage trial tests whether combining two targeted drugs—sunitinib malate and lutetium Lu 177 dotatate (Lutathera)—is safe and effective for people with advanced pancreatic neuroendocrine tumors. The study involves 24 participants and aims to find the best dose while mon…

This early-phase trial tests whether adding the experimental drug CA-4948 to standard chemotherapy (FOLFOX) and a blood-vessel blocker (bevacizumab) is safe and tolerable for people with metastatic colorectal cancer that cannot be removed by surgery. About 24 adults will take par…

This study tests whether adding the drug dinutuximab to standard chemotherapy and surgery helps children with a rare, aggressive nerve cancer called high-risk neuroblastoma. About 478 children up to age 30 will be randomly assigned to receive either standard treatment or standard…

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a protein that boosts immune cells)—can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to prior treatments. About 78 adults will receive the drug…

This study tests whether adding the drug cabozantinib to standard chemotherapy works better than chemo alone for people under 40 with newly diagnosed osteosarcoma, a type of bone cancer. Cabozantinib blocks signals that help tumors grow and form blood vessels. The trial will chec…

This study tests a drug called durvalumab (an immunotherapy) combined with chemotherapy in people with advanced solid tumors that have spread or can't be removed. The goal is to see if the combo is safe and helps the immune system fight the cancer better. About 115 adults whose c…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can better prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people with blood cancers like leukemia or lymphoma. About 2…

This study compares two treatments for people with HER2-positive gynecologic cancers and other solid tumors (excluding breast cancer). One group gets neratinib alone, the other gets neratinib plus palbociclib. Both drugs block signals that make cancer cells grow. The goal is to s…

This early-stage trial tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation is safe for people with advanced pancreatic cancer that cannot be removed by surgery. About 18 participants will receive the treatment after initial chemotherap…

This study tests a drug called daratumumab in people with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. These cancers often do not respond to standard treatments. The drug is given as a shot under t…

This study compares the immunotherapy drug pembrolizumab (Keytruda) alone against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features like posi…

This study tests two drugs, enfortumab vedotin and pembrolizumab, in people with rare bladder or testicular cancers that have spread. About 68 adults will receive the drugs through an IV, either together or alone, for up to 5 years. The goal is to see if the treatment can shrink …

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase study tests whether combining two drugs—pidnarulex and trastuzumab deruxtecan—is safe and effective for people with advanced breast cancer or other solid tumors that have a protein called HER2. The trial enrolls about 36 adults whose cancer has spread, cannot be …

This early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a two-drug pill that makes cancer cells easier to kill)—is safe and effective for people with B-cell lymphoma that has returned or stopped…

This study tests whether a new mix of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease (GVHD) after a half-matched bone marrow transplant in people living with HIV who also have blood cancer. About 265 participants will be enr…

This study tests two non-chemotherapy drugs, PDS01ADC and M7824, in people with advanced Kaposi sarcoma (KS) that has not responded well to prior treatment. PDS01ADC helps the immune system attack tumors, while M7824 blocks cancer cells' ability to hide. The goal is to see if the…

This study tests whether a newer drug, mosunetuzumab, works better than the standard drug rituximab for people with a rare type of Hodgkin lymphoma called NLPHL. Both drugs help the immune system attack cancer cells. About 70 adults who need treatment for their lymphoma will be r…

This study tests a new drug that combines a targeting protein with a radioactive particle to kill cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The goal is to fi…

This early-phase trial tests a new treatment called FGFR4-CAR T cells for children and young adults (ages 3–39) with rhabdomyosarcoma that has come back or not responded to at least two standard treatments. The therapy uses a patient's own immune cells, modified in a lab to bette…

This early-phase study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see how w…

This study tests a drug called TPST-1495 in 38 people with familial adenomatous polyposis (FAP), an inherited condition that causes many polyps in the colon and small bowel and raises colon cancer risk. The drug works by blocking certain signals that help polyps grow. The main go…

This study tests whether a new drug combination (amivantamab plus hyaluronidase) works as well as or better than the standard drug cetuximab for treating skin squamous cell carcinoma that has returned or spread. The trial enrolls 86 immunocompromised adults, including organ trans…

This study tests whether obeticholic acid can prevent cancer in people with Barrett's esophagus, a condition that raises the risk of esophageal cancer. The drug works by reducing damage from bile acids that flow back into the esophagus. About 30 adults with Barrett's esophagus wi…

This study looks at whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can better reduce breast cancer risk in overweight postmenopausal women who are already at higher risk. Tamoxifen blocks estrogen in breast tissue, while omega-3s may help with fat-related canc…

This early-stage trial tests the safety of a drug called ONC201 (dordaviprone) in 36 people with a high risk of colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal tissue. If sa…

This study is developing two questionnaires to help measure how visible tumors affect appearance concerns in people with neurofibromatosis type 1 (NF1). Researchers will interview about 110 participants, including children, adults, and caregivers, to refine the questionnaires. Th…

This study collects white blood cells from healthy volunteers to help researchers develop new cancer treatments that use the body's own immune system. Participants must be 18 or older and in good health. The donation process, called apheresis, takes 4-6 hours and can be repeated …

This study is collecting blood and urine samples from 200 adults with glioblastoma (a serious brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can help predict whether the tumor will come back within one year. The …

This study collects blood, urine, saliva, and tumor tissue from men with or suspected to have prostate cancer. Researchers will study these samples to find genetic changes that cause cancer to grow. The goal is to better understand the disease and develop new treatments. Up to 3,…

This study follows people with Fanconi anemia, a rare inherited condition that raises the risk of certain cancers, especially squamous cell carcinoma. Researchers will screen participants yearly for up to 10 years using exams, blood tests, and imaging to find early signs of cance…

This study follows 195 adults with KSHV-associated multicentric Castleman disease (MCD) to understand how the disease behaves over time. Researchers will track symptoms, treatment responses, and survival. Participants receive standard care and regular check-ups for up to 3 years.…

This study enrolls people with cancer who are already participating in other studies at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a participant's past, current, and future studies. The goal is to better under…

This study follows up to 1,100 people with myelodysplastic syndromes (MDS) and healthy donors for up to 20 years. Researchers collect blood, bone marrow, and other samples to learn how the disease progresses and to find better treatments. No experimental therapy is given; the goa…

This study tests a redesigned surgical tool for removing bladder tumors. The goal is to see if the new device helps doctors get better tissue samples, which may show whether all cancer has been removed. About 25 adults who need their bladder removed will take part. The study only…

This study follows 1,100 adults with common and rare urinary tract cancers (like bladder, kidney, and testicular cancer) to understand how these cancers behave over time. Researchers collect medical records, blood, urine, and tumor samples, and track disease progression and treat…

This study screens up to 2,000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. Researchers test blood and bone marrow for specific markers to see if participants can join a treatment trial that targets their cancer type. The goal is to make the mat…

This study looks at what happens to HIV in the body when people stop their daily HIV medication for a short time. Researchers will use PET/CT scans and lymph node biopsies to compare virus levels in the blood and lymph nodes. The goal is to understand where HIV hides, not to find…

This study collects leftover tissue samples and new samples (blood, cheek swabs, saliva, skin or mouth biopsies) from 1,000 people with head and neck disorders. The goal is to create a repository for future research, including genetic testing, to better understand these condition…

This study collects blood or cheek swab samples from 1,100 people with cancer who are already in an NIH treatment trial. Researchers will analyze the DNA to find genetic differences that might affect how well the treatment works or how likely side effects are. The goal is to bett…

This study is testing a new technology called SmartMatch that checks how a person's brain tumor tissue reacts to different drugs. The goal is to see if the test can give results within 21 days after surgery. About 80 people aged 15 and older with recurrent brain tumors who are al…

This study is for people aged 2 and older with chordoma, a rare bone cancer. Researchers will track how the disease changes over time using scans, exams, and surveys. The goal is to better understand chordoma so future treatments can be designed. Participants will have check-ups …

This study aims to collect tumor, normal tissue, and blood samples from up to 1,310 people with cancers of the lung, esophagus, or chest lining. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify patients who may be eligible f…

This study looks at whether having guided conversations about care preferences helps young adults (ages 18-39) who are about to receive a stem cell transplant, along with their caregivers. Participants will fill out questionnaires and have three talks with a study team member ove…

This study aims to learn how genes and the environment can cause rare tumors and cancer in individuals and families. It does not offer treatment. Up to 500 people of any age who have unusual tumors, a family history of cancer, or certain exposures may join. Participants answer qu…

This study aims to collect tumor and healthy tissue samples from up to 2,415 people scheduled for surgery or biopsy of endocrine tumors (thyroid, parathyroid, adrenal, pancreas, or neuroendocrine). Researchers will analyze the samples to find genetic and molecular differences bet…

This study follows 150 adults with Kaposi sarcoma (KS) to understand how the disease starts, changes, and may come back. Researchers will track participants for up to 10 years using exams, scans, and biopsies. The goal is to learn more about KS, not to test a new treatment. Parti…

This study collects samples like blood, bone marrow, skin, saliva, and stool from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of bone marrow disorders that can lead to blood cancer. Par…

This study looks at anxiety related to cancer screenings in adults with Fanconi anemia, a rare inherited condition that raises cancer risk. Researchers will observe 20 participants during their regular screening visits, noting body language, worries, and the clinic environment. T…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will also track participants' health over time. The goal is to better understand these cancers and support the development of new treatments.

This study aims to collect blood, tissue, and other samples from 200 adults with untreated follicular lymphoma. Researchers will track participants for up to 5 years to see how the cancer evolves and responds to therapy. The goal is to better understand the disease to design futu…

This study aims to understand how neuroendocrine neoplasms (rare cancers of hormone-producing cells) grow and change over time. Researchers will follow 300 adults with these tumors, collecting blood, urine, and tissue samples, and tracking their health yearly. No experimental tre…

This study aims to learn more about RASopathies—a group of genetic conditions that can cause developmental issues, birth defects, and a higher risk of cancer. Researchers will follow up to 500 people of any age who have or may have a RASopathy, along with their family members, fo…

This study follows people who have had a stem cell transplant (and their donors) for many years after the procedure. Researchers want to learn about long-term side effects, how the donated cells change, and how to better fight cancer. Participants will have yearly checkups, blood…